This Article Full Text Full Text (PDF) All Versions of this Article: 25/9/1776    most recent 01.ATV.0000174800.78362.ecv1 Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Frostegård, J. Search for Related Content PubMed PubMed Citation Articles by Frostegård, J. Related Collections Immunity and Atherosclerosis

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2005;25:1776.)
© 2005 American Heart Association, Inc.

Brief Reviews

Atherosclerosis in Patients With Autoimmune Disorders

Johan Frostegård

From the Department of Medicine, Karolinska University Hospital, Huddinge, Center for Infectious Medicine and Unit of Rheumatology, Stockholm, Sweden.

Correspondence to Johan Frostegård, MD, PhD, Department of Medicine, Karolinska University Hospital, Huddinge, Center for Infectious Medicine and Rheumatology Unit, 141 86 Stockholm, Sweden. E-mail johan.frostegard{at}medhs.ki.se

Series Editor: Göran K. Hansson
Immunity and Atherosclerosis
ATVB In Focus

Previous Brief Review in this Series:

•Nilsson J, Hansson GK, Shah PK. Immunomodulation of atherosclerosis: implications for vaccine development. 2005;25:18–28.

Recent findings indicate that presence of activated immune competent cells and inflammation are typical of atherosclerosis, the main cause of cardiovascular disease (CVD). The risk of CVD is very high in a prototypic autoimmune disease, systemic lupus erythematosus (SLE), and is also raised in other autoimmune diseases such as rheumatoid arthritis. Autoimmunity-related CVD and atherosclerosis are important clinical problems. They may also shed light on interactions between immune reactions and atherosclerosis development and manifestations, not least in women, who have a much higher risk of autoimmune disease than men. In general, a combination of traditional and nontraditional risk factors, including dyslipidemia (and to a varying degree, hypertension, diabetes, and smoking), inflammation, antiphospholipid antibodies (aPLs), and lipid oxidation, contribute to CVD in autoimmune diseases. Premature atherosclerosis is likely to be a major underlying mechanism, although distinctive features, if any, of autoimmunity-related atherosclerosis compared with "normal" atherosclerosis are not clear. One interesting possibility is that factors such as inflammation, neoepitopes on endothelial cells, or aPLs make atherosclerotic lesions in autoimmune disease more prone to rupture than in "normal" atherosclerosis. Some cases of autoimmunity-related CVD may be more related to thrombosis than atherosclerosis. Whether premature atherosclerosis is a general feature of autoimmune diseases such as SLE or only affects a subgroup of patients whereas others do not have an increased risk remains to be demonstrated. Treatment of patients with autoimmune disease should also include CVD aspects and be focused on traditional risk factors as well as on disease-related factors. Hopefully novel therapeutic principles will be developed that target the causes of the inflammation present in atherosclerotic lesions.

The risk of cardiovascular disease is very high in systemic lupus erythematosus and is also raised in other autoimmune diseases like rheumatoid arthritis. This may shed light on the role of immune reactions in atherothrombosis. Traditional risk factors and also non-traditional like inflammation, antiphospholipid antibodies and lipid oxidation are implicated.

Key Words: antibodies • atherosclerosis • autoimmunity • inflammation

This article has been cited by other articles:

				T. P. Greco, A. M. Conti-Kelly, T. Greco Jr, R. Doyle, E. Matsuura, J. R. Anthony, and L. R. Lopez Newer Antiphospholipid Antibodies Predict Adverse Outcomes in Patients With Acute Coronary Syndrome Am J Clin Pathol, October 1, 2009; 132(4): 613 - 620. [Abstract] [Full Text] [PDF]

				A Liu, W Zhang, X Tian, X Zhang, F Zhang, and X Zeng Prevalence, risk factors and outcome of digital gangrene in 2684 lupus patients Lupus, October 1, 2009; 18(12): 1112 - 1118. [Abstract] [PDF]

				M. Elshal, A. Abdelaziz, A. Abbas, K. Mahmoud, H. Fathy, S. E. Mongy, S. El-Basyuoni, H. Ahmed, and P. McCoy Quantification of circulating endothelial cells in peripheral blood of systemic lupus erythematosus patients: a simple and reproducible method of assessing endothelial injury and repair Nephrol. Dial. Transplant., May 1, 2009; 24(5): 1495 - 1499. [Abstract] [Full Text] [PDF]

				E. Ammirati, A.-C. Vermi, D. Cianflone, M. Banfi, C. Foglieni, C. Godino, F. Airoldi, L. A. Ferri, C. L. Gorman, A. A. Manfredi, et al. Expansion of T-Cell Receptor {zeta}dim Effector T Cells in Acute Coronary Syndromes Arterioscler Thromb Vasc Biol, December 1, 2008; 28(12): 2305 - 2311. [Abstract] [Full Text] [PDF]

				J. Su, X. Hua, H. Concha, E. Svenungsson, A. Cederholm, and J. Frostegard Natural antibodies against phosphorylcholine as potential protective factors in SLE Rheumatology, August 1, 2008; 47(8): 1144 - 1150. [Abstract] [Full Text] [PDF]

				A. Paul, B. H.-J. Chang, L. Li, V. K. Yechoor, and L. Chan Deficiency of Adipose Differentiation-Related Protein Impairs Foam Cell Formation and Protects Against Atherosclerosis Circ. Res., June 20, 2008; 102(12): 1492 - 1501. [Abstract] [Full Text] [PDF]

				P. S. Olofsson, L. A. Soderstrom, D. Wagsater, Y. Sheikine, P. Ocaya, F. Lang, C. Rabu, L. Chen, M. Rudling, P. Aukrust, et al. CD137 Is Expressed in Human Atherosclerosis and Promotes Development of Plaque Inflammation in Hypercholesterolemic Mice Circulation, March 11, 2008; 117(10): 1292 - 1301. [Abstract] [Full Text] [PDF]

				E. L. Gautier, T. Huby, B. Ouzilleau, C. Doucet, F. Saint-Charles, G. Gremy, M. J. Chapman, and P. Lesnik Enhanced Immune System Activation and Arterial Inflammation Accelerates Atherosclerosis in Lupus-Prone Mice Arterioscler Thromb Vasc Biol, July 1, 2007; 27(7): 1625 - 1631. [Abstract] [Full Text] [PDF]

				P. E Westerweel, R. K M A C Luijten, I. E Hoefer, H. A Koomans, R. H W M Derksen, and M. C Verhaar Haematopoietic and endothelial progenitor cells are deficient in quiescent systemic lupus erythematosus Ann Rheum Dis, July 1, 2007; 66(7): 865 - 870. [Abstract] [Full Text] [PDF]

				C. Cappello, B. Saugel, K. C. Huth, A. Zwergal, M. Krautkramer, C. Furman, M. Rouis, B. Wieser, H. W. Schneider, D. Neumeier, et al. Ozonized Low Density Lipoprotein (ozLDL) Inhibits NF-{kappa}B and IRAK-1-Associated Signaling Arterioscler Thromb Vasc Biol, January 1, 2007; 27(1): 226 - 232. [Abstract] [Full Text] [PDF]

				D. J. A. Jenkins, C. W. C. Kendall, A. R. Josse, S. Salvatore, F. Brighenti, L. S. A. Augustin, P. R. Ellis, E. Vidgen, and A. V. Rao Almonds Decrease Postprandial Glycemia, Insulinemia, and Oxidative Damage in Healthy Individuals J. Nutr., December 1, 2006; 136(12): 2987 - 2992. [Abstract] [Full Text] [PDF]

				H. Methe and E. R. Edelman Cell-Matrix Contact Prevents Recognition and Damage of Endothelial Cells in States of Heightened Immunity Circulation, July 4, 2006; 114(1_suppl): I-233 - I-238. [Abstract] [Full Text] [PDF]